sysa1801
cspc pharmaceuticals,elevation oncology
['sysa1801', 'gastric']
#asco23: cldn18.2 continues being a hot target: $elev sysa1801 showed preliminary activity (47.1% orr) in china-based ph1 trial for gc pts with tolerable toxicity profile; data from larger patient pool warranted. plans to initiate ph1 trial in the us in h2'23 #gastriccancer 
Course5i prides itself in enabling #LifeSciences organizations with insights, #analytics and #AI to drive strategic decisions. Enabling better health outcomes.